Wuhan Mingde Biotechnology Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
On March 23, 2026, the Company held the fourth meeting of the fifth Board of Directors, where it reviewed and approved the proposal for the share buyback plan. The Company intends to use its own funds or self-raised funds to repurchase shares through centralized bidding, aimed at maintaining the Company's value and protecting shareholders' rights. The repurchased shares will be sold in accordance with relevant regulations. The total amount for the buyback will not exceed RMB 200 million and not be less than RMB 100 million, with a repurchase price not exceeding RMB 28 per share. The specific number of shares repurchased will be based on the actual number of shares repurchased by the end of the buyback period. The implementation period for the buyback is within three months from the date the Board of Directors approved the buyback plan.